These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36048456)

  • 21. Distinguishing Frontotemporal Lobar Degeneration Tau From TDP-43 Using Plasma Biomarkers.
    Cousins KAQ; Shaw LM; Chen-Plotkin A; Wolk DA; Van Deerlin VM; Lee EB; McMillan CT; Grossman M; Irwin DJ
    JAMA Neurol; 2022 Nov; 79(11):1155-1164. PubMed ID: 36215050
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated serum Neurofilament Light chain (NfL) as a potential biomarker of neurological involvement in Myotonic Dystrophy type 1 (DM1).
    Nicoletti TF; Rossi S; Vita MG; Perna A; Guerrera G; Lino F; Iacovelli C; Di Natale D; Modoni A; Battistini L; Silvestri G
    J Neurol; 2022 Sep; 269(9):5085-5092. PubMed ID: 35575811
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Usefulness of serum neurofilament light in the assessment of neurologic outcome in the pediatric population: a systematic literature review.
    Jacobs Sariyar A; van Pesch V; Nassogne MC; Moniotte S; Momeni M
    Eur J Pediatr; 2023 May; 182(5):1941-1948. PubMed ID: 36602623
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frontal Intermittent Rhythmic Delta Activity Is a Useful Diagnostic Tool of Neurotoxicity After CAR T-Cell Infusion.
    Huby S; Gelisse P; Tudesq JJ; Labauge P; Duflos C; Cartron G; Gallerand MA; Platon L; Badiou S; Lamure S; Menjot de Champfleur N; Ayrignac X; Taieb G
    Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37059470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum and cerebrospinal fluid neurofilament light chain and glial fibrillary acid protein levels in early and advanced stages of cerebral amyloid Angiopathy.
    Rasing I; Voigt S; Koemans EA; de Kort AM; van Harten TW; van Etten ES; van Zwet EW; Stoops E; Francois C; Kuiperij HB; Klijn CJM; Schreuder FHBM; van der Weerd L; van Osch MJP; van Walderveen MAA; Verbeek MM; Terwindt GM; Wermer MJH
    Alzheimers Res Ther; 2024 Apr; 16(1):86. PubMed ID: 38654326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.
    Gu T; Hu K; Si X; Hu Y; Huang H
    WIREs Mech Dis; 2022 Nov; 14(6):e1576. PubMed ID: 35871757
    [TBL] [Abstract][Full Text] [Related]  

  • 27. EASIX and Severe Endothelial Complications After CD19-Directed CAR-T Cell Therapy-A Cohort Study.
    Korell F; Penack O; Mattie M; Schreck N; Benner A; Krzykalla J; Wang Z; Schmitt M; Bullinger L; Müller-Tidow C; Dreger P; Luft T
    Front Immunol; 2022; 13():877477. PubMed ID: 35464403
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Elevated plasma neurofilament light chain in immune-mediated neurological disorders (IMND) detected by immunomagnetic reduction (IMR).
    Huang KY; Wu CL; Chang YS; Huang WY; Su FC; Lin SW; Chien YY; Weng WC; Wei YC
    Brain Res; 2023 Dec; 1821():148587. PubMed ID: 37739331
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multifocal demyelinating leukoencephalopathy and oligodendroglial lineage cell loss with immune effector cell-associated neurotoxicity syndrome (ICANS) following CD19 CAR T-cell therapy for mantle cell lymphoma.
    Nie EH; Ahmadian SS; Bharadwaj SN; Acosta-Alvarez L; Threlkeld ZD; Frank MJ; Miklos DB; Monje M; Scott BJ; Vogel H
    J Neuropathol Exp Neurol; 2023 Jan; 82(2):160-168. PubMed ID: 36592076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Longitudinal Investigation of Blood Neurofilament Light Chain Levels in Chronic Cocaine Users.
    Bavato F; Kexel AK; Kluwe-Schiavon B; Maceski A; Baumgartner MR; Seifritz E; Kuhle J; Quednow BB
    Mol Neurobiol; 2023 Jul; 60(7):3935-3944. PubMed ID: 37000398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical features of neurotoxicity after CD19 CAR T-cell therapy in mantle cell lymphoma.
    Nie EH; Su YJ; Baird JH; Agarwal N; Bharadwaj S; Weng WK; Smith M; Dahiya S; Han MH; Dunn JE; Kipp LB; Miklos DB; Scott BJ; Frank MJ
    Blood Adv; 2024 Mar; 8(6):1474-1486. PubMed ID: 38295285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Plasma neurofilament light chain in memory clinic practice: Evidence from a real-life study.
    Götze K; Vrillon A; Bouaziz-Amar E; Mouton-Liger F; Hugon J; Martinet M; Dumurgier J; Cognat E; Zetterberg H; Blennow K; Hourrègue C; Paquet C; Lilamand M
    Neurobiol Dis; 2023 Jan; 176():105937. PubMed ID: 36462720
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Neurofilament Light Chain for Prognosis of Outcome After Cardiac Arrest.
    Moseby-Knappe M; Mattsson N; Nielsen N; Zetterberg H; Blennow K; Dankiewicz J; Dragancea I; Friberg H; Lilja G; Insel PS; Rylander C; Westhall E; Kjaergaard J; Wise MP; Hassager C; Kuiper MA; Stammet P; Wanscher MCJ; Wetterslev J; Erlinge D; Horn J; Pellis T; Cronberg T
    JAMA Neurol; 2019 Jan; 76(1):64-71. PubMed ID: 30383090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Managing therapy-associated neurotoxicity in children with ALL.
    Bhojwani D; Bansal R; Wayne AS
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):376-383. PubMed ID: 34889354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of an assay of plasma neurofilament light chain utilizing immunomagnetic reduction technology.
    Liu HC; Lin WC; Chiu MJ; Lu CH; Lin CY; Yang SY
    PLoS One; 2020; 15(6):e0234519. PubMed ID: 32530970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes.
    Marks JD; Syrjanen JA; Graff-Radford J; Petersen RC; Machulda MM; Campbell MR; Algeciras-Schimnich A; Lowe V; Knopman DS; Jack CR; Vemuri P; Mielke MM;
    Alzheimers Res Ther; 2021 Dec; 13(1):199. PubMed ID: 34906229
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes of neurofilament light chain in patients with alcohol dependence following withdrawal and the genetic effect from ALDH2 Polymorphism.
    Huang MC; Tu HY; Chung RH; Kuo HW; Liu TH; Chen CH; Mochly-Rosen D; Liu YL
    Eur Arch Psychiatry Clin Neurosci; 2024 Mar; 274(2):423-432. PubMed ID: 37314537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell Encephalopathy (ICE) Score.
    Herr MM; Chen GL; Ross M; Jacobson H; McKenzie R; Markel L; Balderman SR; Ho CM; Hahn T; McCarthy PL
    Biol Blood Marrow Transplant; 2020 Nov; 26(11):e271-e274. PubMed ID: 32736009
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Plasma Neurofilament Light Chain Levels as a Biomarker of Neuronal Injury in the Active and Chronic Phases of Autoimmune Neurologic Disorders.
    Kammeyer R; Mizenko C; Sillau S; Richie A; Owens G; Nair KV; Alvarez E; Vollmer TL; Bennett JL; Piquet AL
    Front Neurol; 2022; 13():689975. PubMed ID: 35309573
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy.
    Maalmi H; Strom A; Petrera A; Hauck SM; Strassburger K; Kuss O; Zaharia OP; Bönhof GJ; Rathmann W; Trenkamp S; Burkart V; Szendroedi J; Ziegler D; Roden M; Herder C;
    Diabetologia; 2023 Mar; 66(3):579-589. PubMed ID: 36472640
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.